Gerresheimer (GXI) Aktievy
Gerresheimer AG, tillsammans med sina dotterbolag, tillverkar och säljer läkemedelsförpackningar, utrustning för läkemedelstillförsel och lösningar i Tyskland och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 1/6 |
| Finansiell hälsa | 0/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
GXI Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Gerresheimer AG Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €26.42 |
| 52 veckors högsta | €52.00 |
| 52 veckors lägsta | €14.83 |
| Beta | 0.47 |
| 1 månads förändring | -3.51% |
| 3 månaders förändring | 28.38% |
| 1 års förändring | -44.36% |
| 3 års förändring | -74.37% |
| 5 års förändring | -71.65% |
| Förändring sedan börsintroduktionen | -31.11% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 16
GXI: Reporting Delays Accounting Scrutiny And Bormioli Overhang Will Cap Near Term Confidence
Gerresheimer's updated analyst price target has come down to €26.80 from €34.10. Analysts point to delayed results, accounting concerns and ongoing overhangs around Bormioli as key reasons for the reset.Uppdatering av berättelse • Jun 01
GXI: Reporting Delays And Accounting Concerns Will Pressure Long Term Confidence
Analysts have trimmed their price targets on Gerresheimer, with one cut from €34.10 to €26.80 contributing to a modest reduction in the modelled fair value from €24.40 to about €23.37, as concerns around delayed results, accounting issues, and the Bormioli overhang weigh on sentiment. Analyst Commentary Recent research has shifted toward a more cautious stance on Gerresheimer, with several firms moving to neutral ratings and cutting price targets to around €26.80 from about €34.10.
Uppdatering av berättelse • May 03
GXI: FY25 Warning And Deferred Results Will Drive Further Share Weakness
Analysts have trimmed their average price target for Gerresheimer to about €12.90 from €29, citing reduced short- and mid-term estimates following the recent FY25 warning and slightly softer expectations compared with the low end of the company's FY26 guidance. Analyst Commentary Bearish analysts are flagging a more cautious stance on Gerresheimer, pointing to reduced confidence in near term execution and visibility.
Uppdatering av berättelse • Apr 19
GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations
Gerresheimer's analyst price target has been revised lower to €44.18 from €45.95 as analysts factor in reduced short and mid term estimates following the recent FY25 warning and expectations that FY26 performance may sit near the low end of company guidance. Analyst Commentary The recent revision of the consensus price target to €44.18 reflects how analysts are resetting expectations after the FY25 warning and a more cautious view on FY26, which some see as closer to the low end of company guidance.Recent updates
Uppdatering av berättelse • Jun 16
GXI: Reporting Delays Accounting Scrutiny And Bormioli Overhang Will Cap Near Term Confidence
Gerresheimer's updated analyst price target has come down to €26.80 from €34.10. Analysts point to delayed results, accounting concerns and ongoing overhangs around Bormioli as key reasons for the reset.Uppdatering av berättelse • Jun 01
GXI: Reporting Delays And Accounting Concerns Will Pressure Long Term Confidence
Analysts have trimmed their price targets on Gerresheimer, with one cut from €34.10 to €26.80 contributing to a modest reduction in the modelled fair value from €24.40 to about €23.37, as concerns around delayed results, accounting issues, and the Bormioli overhang weigh on sentiment. Analyst Commentary Recent research has shifted toward a more cautious stance on Gerresheimer, with several firms moving to neutral ratings and cutting price targets to around €26.80 from about €34.10.Uppdatering av berättelse • May 03
GXI: FY25 Warning And Deferred Results Will Drive Further Share Weakness
Analysts have trimmed their average price target for Gerresheimer to about €12.90 from €29, citing reduced short- and mid-term estimates following the recent FY25 warning and slightly softer expectations compared with the low end of the company's FY26 guidance. Analyst Commentary Bearish analysts are flagging a more cautious stance on Gerresheimer, pointing to reduced confidence in near term execution and visibility.Uppdatering av berättelse • Apr 19
GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations
Gerresheimer's analyst price target has been revised lower to €44.18 from €45.95 as analysts factor in reduced short and mid term estimates following the recent FY25 warning and expectations that FY26 performance may sit near the low end of company guidance. Analyst Commentary The recent revision of the consensus price target to €44.18 reflects how analysts are resetting expectations after the FY25 warning and a more cautious view on FY26, which some see as closer to the low end of company guidance.Uppdatering av berättelse • Apr 05
GXI: FY26 Guidance Anchor And Lowered Expectations Will Support Long-Term Confidence
The consensus analyst price target for Gerresheimer has decreased from about €34.17 to €24.40. Analysts cite reduced short- and mid-term estimates following the recent FY25 warning, and their FY26 expectations are now slightly below the low end of company guidance.Uppdatering av berättelse • Mar 22
GXI: FY25 Warning And Deferred Results Will Pressure Shares Further
Analysts have reduced their price target for Gerresheimer to about €12.50 from around €18.90, citing lower short- and mid-term estimates following the recent FY25 warning and expectations that FY26 outcomes could sit near the low end of company guidance. Analyst Commentary Bearish analysts are signaling a more cautious view on Gerresheimer following the recent FY25 warning, with fresh price targets pointing to a more conservative stance on both earnings power and execution over the next few years.Uppdatering av berättelse • Mar 07
GXI: Reset After FY25 Warning Will Set Up Future Earnings Reappraisal
Analysts have reduced their price target for Gerresheimer to about €46 from about €52, citing a higher discount rate and lower assumed future P/E, along with updated revenue growth and profit margin assumptions, as well as recent cautious Street research following the FY25 warning. Analyst Commentary The latest Street research has turned more cautious after the FY25 warning, with at least one major broker shifting to a Sell stance and cutting its price target to €12.90 from €29.Uppdatering av berättelse • Feb 21
GXI: Deferred Results And Softer Outlook Will Keep Shares Fairly Priced
Analysts have adjusted their price target on Gerresheimer to €18.90 from €22.00 as they now apply a slightly higher discount rate, a lower assumed revenue growth rate, a modestly higher profit margin, and a reduced future P/E multiple. What's in the News Gerresheimer issued earnings guidance for 2026, targeting revenues of around €2.3b to €2.4b (company guidance).Analysartikel • Feb 10
Investors Don't See Light At End Of Gerresheimer AG's (ETR:GXI) Tunnel
Gerresheimer AG's ( ETR:GXI ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a buy right now compared...Uppdatering av berättelse • Feb 06
GXI: Index Inclusion And Higher P/E Assumptions Will Support Long-Term Confidence
Analysts have modestly lifted their price target for Gerresheimer, citing small adjustments to fair value and discount rate assumptions, as well as revised expectations for revenue growth, profit margins and future P/E. What's in the News Gerresheimer AG has been added to the Germany SDAX (Total Return) Index, highlighting its inclusion in this segment of the German equity market (Key Developments).Uppdatering av berättelse • Jan 23
GXI: Reset Expectations Will Set Up Future Reappraisal Of Earnings Quality
Analysts have trimmed their average price target on Gerresheimer to €30 from €55. The change reflects updated expectations for revenue growth, profit margins and future P/E multiples following recent research reviews.Uppdatering av berättelse • Jan 09
GXI: Profit Warnings Reset Expectations While Drug Delivery Platform Will Drive Reassessment
Gerresheimer's updated fair value estimate has been cut from about €97.07 to around €51.97 as analysts reset price targets sharply lower, citing reduced earnings visibility, a higher discount rate and increased uncertainty following recent profit warnings and rating downgrades. Analyst Commentary Recent Street research has turned more cautious on Gerresheimer, with several firms lowering price targets and adjusting ratings following profit warnings and reduced visibility on the investment case.Uppdatering av berättelse • Dec 25
GXI: Profit Warnings And Weak Outlook Will Pressure Shares Further
Gerresheimer's analyst price target has been cut sharply from about EUR 47.50 to EUR 22.00, as analysts factor in lower growth, thinner margins, a higher discount rate, and reduced valuation multiples following multiple target downgrades and rising uncertainty around the investment case. Analyst Commentary Bearish analysts have made a series of aggressive downward revisions to Gerresheimer's valuation, cutting price targets from prior levels as high as EUR 99.30 to a range between EUR 23 and EUR 46.Uppdatering av berättelse • Dec 11
GXI: Long-Term Sector Demand Will Support Confidence Despite Recent Profit Warnings
Analysts have cut their price target on Gerresheimer sharply, from roughly EUR 35 to about EUR 34. This reflects reduced fair value estimates as they factor in lower visibility on the investment case, successive target downgrades across the Street, and ongoing uncertainty following multiple profit warnings.Analysartikel • Nov 30
These 4 Measures Indicate That Gerresheimer (ETR:GXI) Is Using Debt In A Risky Way
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Uppdatering av berättelse • Nov 27
GXI: Long-Term Sector Demand Will Support Confidence After Recent Leadership Change
Gerresheimer's analyst price targets have been significantly reduced recently, with analysts citing ongoing uncertainties and diminished near-term visibility as key factors for the downward revision. Previous targets exceeded €50, but new values are now in the €23 to €46 range.Uppdatering av berättelse • Nov 10
GXI: Confidence Will Remain Despite Current Uncertainties And Leadership Transition
Gerresheimer's analyst fair value target has been revised downward from €37.84 to €34.62. This change reflects recent broad cuts in price targets by analysts, who cite low visibility and ongoing uncertainties around the company's outlook.Analysartikel • Nov 02
Lacklustre Performance Is Driving Gerresheimer AG's (ETR:GXI) 27% Price Drop
To the annoyance of some shareholders, Gerresheimer AG ( ETR:GXI ) shares are down a considerable 27% in the last...Uppdatering av berättelse • Oct 27
Ongoing Uncertainties And Downgrades Will Shape Efficiency Efforts Ahead
Gerresheimer's analyst price target has been significantly reduced from €56.36 to €37.84. Analysts cite heightened uncertainties, reduced growth expectations, and a lack of near-term catalysts as reasons for this more cautious outlook.Uppdatering av berättelse • Oct 13
New Production Lines In Lohr And Skopje Will Improve Efficiency
Analysts have lowered their price target for Gerresheimer from €63.72 to €56.36. They cite more cautious expectations for revenue growth and profitability going forward.Uppdatering av berättelse • Sep 23
New Production Lines In Lohr And Skopje Will Improve Efficiency
The downward revision in Gerresheimer’s price target reflects recent declines in both net profit margin and consensus revenue growth forecasts, resulting in a reduced fair value estimate from €66.84 to €63.72. What's in the News Wolf Lehmann appointed as incoming CFO, succeeding Dr. Bernd Metzner; Lehmann brings nearly 30 years of international finance and management experience.Analysartikel • Sep 18
Why We're Not Concerned About Gerresheimer AG's (ETR:GXI) Share Price
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Analysartikel • Jul 31
Here's Why Gerresheimer (ETR:GXI) Is Weighed Down By Its Debt Load
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Jun 18
Positive Sentiment Still Eludes Gerresheimer AG (ETR:GXI) Following 28% Share Price Slump
Unfortunately for some shareholders, the Gerresheimer AG ( ETR:GXI ) share price has dived 28% in the last thirty days...Analysartikel • May 30
Shareholders May Be Wary Of Increasing Gerresheimer AG's (ETR:GXI) CEO Compensation Package
Key Insights Gerresheimer's Annual General Meeting to take place on 5th of June Salary of €1.15m is part of CEO Dietmar...Analysartikel • May 29
Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Gerresheimer AG ( ETR:GXI ) will pay a dividend of €1.25 on the 10th of June. Based on this payment, the dividend yield...Analysartikel • May 14
Is There Now An Opportunity In Gerresheimer AG (ETR:GXI)?
Gerresheimer AG ( ETR:GXI ), is not the largest company out there, but it led the XTRA gainers with a relatively large...Analysartikel • Apr 24
Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
Gerresheimer AG ( ETR:GXI ) has announced that it will pay a dividend of €1.25 per share on the 10th of June. Based on...Analysartikel • Apr 19
Earnings Troubles May Signal Larger Issues for Gerresheimer (ETR:GXI) Shareholders
Gerresheimer AG's ( ETR:GXI ) recent weak earnings report didn't cause a big stock movement. However, we believe that...Analysartikel • Apr 11
It's Down 32% But Gerresheimer AG (ETR:GXI) Could Be Riskier Than It Looks
Gerresheimer AG ( ETR:GXI ) shares have had a horrible month, losing 32% after a relatively good period beforehand. The...Analysartikel • Apr 10
Gerresheimer (ETR:GXI) Will Pay A Dividend Of €1.25
Gerresheimer AG's ( ETR:GXI ) investors are due to receive a payment of €1.25 per share on 10th of June. This means the...Analysartikel • Mar 05
Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
The board of Gerresheimer AG ( ETR:GXI ) has announced that it will pay a dividend on the 10th of June, with investors...Analysartikel • Feb 25
Why Investors Shouldn't Be Surprised By Gerresheimer AG's (ETR:GXI) 25% Share Price Surge
Gerresheimer AG ( ETR:GXI ) shareholders would be excited to see that the share price has had a great month, posting a...
Ny berättelse • Feb 09
Expansion Into High-Margin Biologics And Devices Indicates Strong Future Prospects
Strategic expansion into high-margin segments like drug delivery systems and ready-to-use vials could enhance revenue and EBITDA margins significantly.Analysartikel • Jan 12
Is Gerresheimer (ETR:GXI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Dec 26
Is It Time To Consider Buying Gerresheimer AG (ETR:GXI)?
While Gerresheimer AG ( ETR:GXI ) might not have the largest market cap around , it saw significant share price...Analysartikel • Oct 03
Gerresheimer AG Just Missed EPS By 14%: Here's What Analysts Think Will Happen Next
It's been a mediocre week for Gerresheimer AG ( ETR:GXI ) shareholders, with the stock dropping 20% to €77.50 in the...Analysartikel • Sep 29
Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysartikel • Aug 31
Gerresheimer AG's (ETR:GXI) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 31x Gerresheimer AG ( ETR:GXI ) may be sending very bearish signals at the...Aktieägarnas avkastning
| GXI | DE Life Sciences | DE Marknad | |
|---|---|---|---|
| 7D | 1.9% | 5.7% | -0.8% |
| 1Y | -44.4% | -9.4% | 2.2% |
Avkastning vs industri: GXI presterade sämre än German Life Sciences branschen som gav -9.4 % under det senaste året.
Avkastning vs Marknaden: GXI presterade sämre än German marknaden som gav 2.2 % under det senaste året.
Prisvolatilitet
| GXI volatility | |
|---|---|
| GXI Average Weekly Movement | 8.2% |
| Life Sciences Industry Average Movement | 7.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.8% |
Stabil aktiekurs: GXI s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för German.
Volatilitet över tid: GXI s veckovolatilitet ( 8% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av German aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1864 | 13,535 | Uwe Röehrhoff | www.gerresheimer.com |
Gerresheimer AG, tillsammans med sina dotterbolag, tillverkar och säljer läkemedelsförpackningar, utrustning för läkemedelstillförsel och lösningar i Tyskland och internationellt. Verksamheten bedrivs genom tre divisioner: Plastics & Devices, Primary Packaging Glass och Advanced Technologies. Företaget erbjuder förfyllningsbara sprutor, förpackningslösningar i plast och glas, vialer, glaspatroner och ampuller, flaskor och behållare, glasflaskor och burkar samt kapsyler, förslutningar, applikatorer och tillbehör; utveckling, industrialisering och kontraktstillverkning av program för läkemedelstillförsel; projekt- och kvalitetsledning; och system för läkemedelstillförsel, inklusive inhalatorer, injektions-/autoinjektorer, penninjektorer, infusionssystem och inhalationsbedömning, autoinjektorer och andra tjänster.
Gerresheimer AG Sammanfattning av grunderna
| GXI grundläggande statistik | |
|---|---|
| Börsvärde | €912.55m |
| Vinst(TTM) | €23.35m |
| Intäkter(TTM) | €2.25b |
39.1x
P/E-förhållande0.4x
P/S-förhållandeÄr GXI övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| GXI resultaträkning (TTM) | |
|---|---|
| Intäkter | €2.25b |
| Kostnad för intäkter | €1.65b |
| Bruttovinst | €605.15m |
| Övriga kostnader | €581.80m |
| Intäkter | €23.35m |
Senast redovisade vinst
Aug 31, 2025
Nästa vinstdatum
Jul 14, 2026
| Vinst per aktie (EPS) | 0.68 |
| Bruttomarginal | 26.89% |
| Nettovinstmarginal | 1.04% |
| Skuld/egenkapitalförhållande | 155.5% |
Hur har GXI utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.2%
Aktuell utdelningsavkastning6%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/25 09:52 |
| Aktiekurs vid dagens slut | 2026/06/25 00:00 |
| Intäkter | 2025/08/31 |
| Årlig intjäning | 2024/11/30 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Gerresheimer AG bevakas av 34 analytiker. 12 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jonathon Unwin | Barclays |
| Pallav Mittal | Barclays |
| Gaurav Jain | Barclays |